1 / 13

Clyde W. Yancy, M.D. on behalf of the FUSION II Steering Committee

Results of the Follow-up Serial Infusions of Nesiritide for the Management of Patients With [Advanced] Heart Failure (FUSION II) Trial American College of Cardiology 56 th Annual Scientific Session New Orleans, Louisiana March 25, 2007. Clyde W. Yancy, M.D.

manton
Download Presentation

Clyde W. Yancy, M.D. on behalf of the FUSION II Steering Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Results of the Follow-up Serial Infusions of Nesiritide for the Management of Patients With [Advanced] Heart Failure (FUSION II) TrialAmerican College of Cardiology56th Annual Scientific SessionNew Orleans, LouisianaMarch 25, 2007 Clyde W. Yancy, M.D. on behalf of the FUSION II Steering Committee Henry Krum, MD; Barry M. Massie, MD; Marc A Silver, MD; Lynne W. Stevenson, MD and the FUSION II Investigators

  2. FUSION I: Mortality & All-cause Hospitalization (High Risk Patients- ACC/AHA Stage D HF or ‘CDHF’) P=0.03 P=0.23

  3. FUSION II Study Design Nesiritide* 2x/wk +Intensive Disease Management (n = 300) Placebo 2x/wk +Intensive Disease Management (n = 150) n = 900 Nesiritide* 1x/wk +Intensive Disease Management (n = 300) Phase IIb Double-blind Randomized Multi-center Placebo 1x/wk +Intensive Disease Management (n = 150) 12 week blinded follow-up period 12 week treatment period *Dosing: 2 g/kg bolus, then 0.01 g/kg /min infusion x 4-6 hours 1° and 2° Endpoints AdditionalEndpoints Yancy CW et al. Am Heart J 2007; in press. Available online 3/10/2007, DOI: 10.1016/j.ahj.2007.02.004

  4. Efficacy Endpoints • Primary • Time to all cause death or first CV and/or renal hospitalization through Week 12 • Secondary* • Number of CV and/or renal hospitalizations adjusted for observation period duration • Days alive and out of hospital • Change in KCCQ summary score • Time to CV death *from day of randomization through week 12, or week 13 for KCCQ Yancy CW et al. Am Heart J 2007; in press. Available online 3/10/2007, DOI: 10.1016/j.ahj.2007.02.004

  5. Demographics

  6. 530% increase 56% increase 160% increase Baseline TherapyFUSION I vs. FUSION II Percent of patients treated *Includes both carvedilol and extended release metoprolol in FUSION II and any beta- blocker in FUSION I

  7. Inotrope InfusionsFUSION I vs FUSION II FUSION I FUSION I Percent of patients treated FUSION II FUSION II Pre-randomization Inotropes Outpatient Inotropes During Study *Refers to exposure to inotropes within 2 weeks of randomization

  8. FUSION II: Primary Composite Endpoint Through Week 12 *P value: NES vs. placebo stratified by dose group †Modified ITT: all treated ITT patients

  9. FUSION II: Secondary Endpoints Week 12 *P value nesiritide vs. placebo stratified by dose group

  10. SAFETY Any Adverse Event AE: Adverse event SAE: Serious adverse event that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity.

  11. SAFETY Protocol Specified Changes in Serum Creatinine* P=0.046 Percent of patients with SCr increases P=0.931 P=0.458 *Outpatient Clinic Visit Values Only

  12. FUSION II – Conclusions • In this patient population with advanced HF and serial infusions of nesiritide: • No evidence of drug induced renal harm compared to placebo • No evidence of increased mortality at pre-specified endpoints

  13. FUSION II - Conclusions • In the context of optimal adherence to evidence based medical and device therapies and in concert with excellent disease management, serial infusions of nesiritide did not result in a demonstrable clinical benefit over intensive outpatient management of patients with CDHF • Adherence to guideline based therapy AND meticulous follow-up should be optimized for patients with CDHF

More Related